TY - JOUR
T1 - Outcomes of the first global multidisciplinary consensus meeting including persons living with obesity to standardize patient-reported outcome measurement in obesity treatment research
AU - de Vries, Claire E.E.
AU - Terwee, Caroline B.
AU - Al Nawas, May
AU - van Wagensveld, Bart A.
AU - Janssen, Ignace M.C.
AU - Liem, Ronald S.L.
AU - Nienhuijs, Simon W.
AU - Cohen, Ricardo V.
AU - van Rossum, Elisabeth F.C.
AU - Brown, Wendy A.
AU - Ghaferi, Amir A.
AU - Ottosson, Johan
AU - Coulman, Karen D.
AU - Petry, Tarissa B.Z.
AU - Sogg, Stephanie
AU - West-Smith, Lisa
AU - Halford, Jason C.G.
AU - Salas, Ximena Ramos
AU - Dixon, John B.
AU - Al-Sabah, Salman
AU - Lee, Wei Jei
AU - Andersen, John Roger
AU - Flint, Stuart W.
AU - Hoogbergen, Maarten M.
AU - Backman, Brooke
AU - Govers, Ellen
AU - Isack, Nadya
AU - Clay, Caroline
AU - Birney, Susie
AU - Gunn, Maureen
AU - Masterson, Paul
AU - Roberts, Audrey
AU - Nesbitt, Jacky
AU - Meloni, Riccardo
AU - le Brocq, Sarah
AU - de Blaeij, Sandra
AU - Kraaijveld, Christina
AU - van der Steen, Floor
AU - Visser, Bibian
AU - Hamers, Petra
AU - Monpellier, Valerie M.
N1 - Funding Information:
None of the members of the organizing committee (C.V., V.M., B.W., I.J., and R.L.) and none of the participants received payment for their participation. Travel expenses and the hotel overnight for the face‐to‐face meeting of the S.Q.O.T. were supported by Medtronic, Johnson & Johnson, Philips Vital Health, Novo Nordisk, Castor and Bart Torensma. C.V. and V.M. are the founders of the S.Q.O.T. initiative, B.W., I.J., and R.L. are cofounders of the S.Q.O.T. initiative. R.C. received lecture, presentations, speakers bureaus, manuscript writing, or educational events fees for Johnson & Johnson, Medtronic, Jansen Pharmaceutical, Novo Nordisk, BAriatec, and GI Dynamics; a research grant from Medtronic; consulting fees from Johnson & Johnson and Medtronic. X.R.S. received lecture, presentations, speakers bureaus, manuscript writing, or educational events fees for Obesity Canada, the European Association for the Study of Obesity, and the World Health Organization Regional Office for Europe; conference travel fees from Obesity Canada, the European Association for the Study of Obesity, the World Health Organization Regional Office for Europe, World Obesity Federation, The Obesity Society, and Novo Nordisk consulting fees from Obesity Canada, the European Association for the Study of Obesity, and the World Health Organization Regional Office for Europe; is co‐chair of the World Obesity Federation Working Group on Weight Bias and Stigma, member of The Obesity Society Policy and Advocacy Committee, and founding member of the Obesity Canada EveryBODY Matters Collaborative (unpaid); owns a research and communications company through which she conducts her consulting work (K&X Ramos AB). R.L. received lecture, presentations, speakers bureaus, manuscript writing, or educational events fees for Johnson & Johnson, Medtronic. S.F. received academic conference attendance fees from Johnson & Johnson and Novo Nordisk. B.B. received from Monash University funding support for attendance, as the main account holders of the funding received from the Department of Health, Commonwealth of Australia. Monash University did not provide any additional funding or financial support for the attendance outside of the grant funding money as explained above. W.B. received lecture, presentations, speakers bureaus, manuscript writing, or educational events fees for Merck Sharpe and Dohme, Novo Nordisk, and Gore; research grants from Medtronic, Johnson & Johnson, Gore, Applied Medical, Novo Nordisk, and Commonwealth Government of Australia; conference travel fees from Novo Nordisk. All other authors declare that they have no conflict of interest.
Funding Information:
The S.Q.O.T. meeting was funded by Medtronic, Johnson & Johnson, Philips Vital Health, Novo Nordisk, Castor and Bart Torensma. The funders of the meeting were not involved in the selection of the domains and questionnaires included in this meeting. These sponsors played no role in the selection of participants of the meeting, in the selection of the domains and questionnaires included in this meeting, the voting rounds, or the writing of this paper.
Publisher Copyright:
© 2022 The Authors. Obesity Reviews published by John Wiley & Sons Ltd on behalf of World Obesity Federation.
PY - 2022/8
Y1 - 2022/8
N2 - Quality of life is a key outcome that is not rigorously measured in obesity treatment research due to the lack of standardization of patient-reported outcomes (PROs) and PRO measures (PROMs). The S.Q.O.T. initiative was founded to Standardize Quality of life measurement in Obesity Treatment. A first face-to-face, international, multidisciplinary consensus meeting was conducted to identify the key PROs and preferred PROMs for obesity treatment research. It comprised of 35 people living with obesity (PLWO) and healthcare providers (HCPs). Formal presentations, nominal group techniques, and modified Delphi exercises were used to develop consensus-based recommendations. The following eight PROs were considered important: self-esteem, physical health/functioning, mental/psychological health, social health, eating, stigma, body image, and excess skin. Self-esteem was considered the most important PRO, particularly for PLWO, while physical health was perceived to be the most important among HCPs. For each PRO, one or more PROMs were selected, except for stigma. This consensus meeting was a first step toward standardizing PROs (what to measure) and PROMs (how to measure) in obesity treatment research. It provides an overview of the key PROs and a first selection of the PROMs that can be used to evaluate these PROs.
AB - Quality of life is a key outcome that is not rigorously measured in obesity treatment research due to the lack of standardization of patient-reported outcomes (PROs) and PRO measures (PROMs). The S.Q.O.T. initiative was founded to Standardize Quality of life measurement in Obesity Treatment. A first face-to-face, international, multidisciplinary consensus meeting was conducted to identify the key PROs and preferred PROMs for obesity treatment research. It comprised of 35 people living with obesity (PLWO) and healthcare providers (HCPs). Formal presentations, nominal group techniques, and modified Delphi exercises were used to develop consensus-based recommendations. The following eight PROs were considered important: self-esteem, physical health/functioning, mental/psychological health, social health, eating, stigma, body image, and excess skin. Self-esteem was considered the most important PRO, particularly for PLWO, while physical health was perceived to be the most important among HCPs. For each PRO, one or more PROMs were selected, except for stigma. This consensus meeting was a first step toward standardizing PROs (what to measure) and PROMs (how to measure) in obesity treatment research. It provides an overview of the key PROs and a first selection of the PROMs that can be used to evaluate these PROs.
KW - obesity treatment
KW - patient-reported outcome measures
KW - patient-reported outcomes
KW - quality of life
UR - http://www.scopus.com/inward/record.url?scp=85131003761&partnerID=8YFLogxK
U2 - 10.1111/obr.13452
DO - 10.1111/obr.13452
M3 - Article
C2 - 35644939
AN - SCOPUS:85131003761
SN - 1467-7881
VL - 23
JO - Obesity Reviews
JF - Obesity Reviews
IS - 8
M1 - e13452
ER -
